The Manufacturers Life Insurance Company lessened its holdings in Enovis Co. (NYSE:ENOV – Get Rating) by 2.1% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 38,527 shares of the company's stock after selling 841 shares during the period. The Manufacturers Life Insurance Company owned about 0.07% of Enovis worth $1,775,000 as of its most recent SEC filing.
Other institutional investors have also recently bought and sold shares of the company. Wipfli Financial Advisors LLC bought a new position in Enovis during the third quarter valued at about $36,000. Paloma Partners Management Co acquired a new stake in Enovis during the second quarter worth about $209,000. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Enovis during the second quarter worth about $261,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in Enovis during the second quarter valued at approximately $285,000. Finally, TAGStone Capital Inc. acquired a new stake in Enovis during the second quarter valued at approximately $288,000. Institutional investors and hedge funds own 96.73% of the company's stock.
Get Enovis alerts:Insider Activity at Enovis
In related news, CFO Christopher M. Hix sold 1,367 shares of the business's stock in a transaction on Wednesday, December 14th. The shares were sold at an average price of $55.28, for a total value of $75,567.76. Following the transaction, the chief financial officer now owns 44,605 shares in the company, valued at $2,465,764.40. The transaction was disclosed in a document filed with the SEC, which is available through this link. In other news, CFO Christopher M. Hix sold 1,367 shares of the company's stock in a transaction dated Wednesday, December 14th. The shares were sold at an average price of $55.28, for a total transaction of $75,567.76. Following the transaction, the chief financial officer now owns 44,605 shares in the company, valued at $2,465,764.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Daniel A. Pryor sold 67,421 shares of the company's stock in a transaction dated Tuesday, November 15th. The shares were sold at an average price of $54.58, for a total transaction of $3,679,838.18. Following the transaction, the executive vice president now owns 75,731 shares in the company, valued at approximately $4,133,397.98. The disclosure for this sale can be found here. 8.30% of the stock is owned by company insiders.
Analyst Ratings Changes
Several research analysts recently weighed in on the stock. Robert W. Baird dropped their price objective on shares of Enovis from $73.00 to $68.00 and set an "outperform" rating for the company in a research report on Thursday, November 3rd. The Goldman Sachs Group started coverage on shares of Enovis in a research report on Tuesday, October 11th. They set a "buy" rating and a $57.00 price objective for the company. Jefferies Financial Group initiated coverage on shares of Enovis in a research report on Wednesday, October 12th. They issued a "buy" rating and a $60.00 price target for the company. Evercore ISI lifted their price objective on shares of Enovis to $68.00 in a research note on Tuesday, January 3rd. Finally, TheStreet cut shares of Enovis from a "c" rating to a "d" rating in a research note on Wednesday, November 2nd. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, Enovis has a consensus rating of "Moderate Buy" and a consensus target price of $63.50.Enovis Stock Performance
Shares of NYSE:ENOV opened at $65.25 on Friday. The firm has a market cap of $3.53 billion, a PE ratio of 135.94 and a beta of 2.04. The firm's fifty day moving average is $56.85 and its 200-day moving average is $53.96. Enovis Co. has a 52 week low of $43.88 and a 52 week high of $129.21.
Enovis (NYSE:ENOV – Get Rating) last released its earnings results on Wednesday, November 2nd. The company reported $0.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.47 by $0.12. The business had revenue of $383.81 million for the quarter, compared to analyst estimates of $379.75 million. Enovis had a net margin of 0.94% and a return on equity of 4.46%. Sell-side analysts forecast that Enovis Co. will post 2.24 EPS for the current year.
Enovis Company Profile
(Get Rating)
Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries.
Featured Stories
- Get a free copy of the StockNews.com research report on Enovis (ENOV)
- Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
- Zimmer Biomet Beats on Earnings, Growth May be Priced In
- AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
- Ford Stock Going Forward After Big Earnings Flop
- Insiders And Institutions Buy Wolverine Worldwide
Want to see what other hedge funds are holding ENOV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enovis Co. (NYSE:ENOV – Get Rating).
Receive News & Ratings for Enovis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovis and related companies with MarketBeat.com's FREE daily email newsletter.